The Impact of Baseline Risk Factors on the Incidence of Febrile Neutropenia in Breast Cancer Patients Receiving Chemotherapy with Pegfilgrastim Prophylaxis: A Real-World Data Analy... by Edward Li, Bridgette Kanz Schroader, David Campbell, Kim Campbell, Weijia Wang

Get full text

A Critical Review of Theory in Social Work Journals: A Replication Study by Carolyn S. Gentle-Genitty, Virgil Gregory, Corey Pfahler, Misty Thomas, Lisa Lewis, Kim Campbell, Kathy Ballard, Kathy Compton, James G. Daley

Get full text

Development of patient-centered outcomes for labour and birth: a qualitative study by Geoffrey E. Johnson, Lauren Kan, Jennifer Nguyen, Kim Campbell, Laura Ralph, Nicole Koenig, May Sanaee, Ciana Maher, Geoffrey W. Cundiff

Get full text

Using a wearable patch to develop a digital monitoring biomarker of inflammation in response to LPS challenge by Stefan Avey, Meenakshi Chatterjee, Nikolay V. Manyakov, Philip Cooper, Nina Sabins, Kenneth Mosca, Simone Mori, Frédéric Baribaud, Mark Morris, Joseph Lehar, Annemie Deiteren, Marta Cossu, Sophie Smets, Tanja Huizer, Esi Lamousé‐Smith, Kim Campbell, Ioannis Pandis

Get full text

Therapeutic Plasma Exchange Is Associated With Improved Major Adverse Kidney Events in Children and Young Adults With Thrombocytopenia at the Time of Continuous Kidney Replacement... by Dana Y. Fuhrman, DO, MS, Sameer Thadani, MD, Claire Hanson, MD, Joseph A. Carcillo, MD, John A. Kellum, MD, Hyun Jung Park, PhD, Liling Lu, MS, Nahmah Kim-Campbell, MD, MS, Christopher M. Horvat, MD, MHA, Ayse Akcan Arikan, MD

Get full text

Randomized phase I trial of antigen-specific tolerizing immunotherapy with peptide/calcitriol liposomes in ACPA+ rheumatoid arthritis by Amee Sonigra, Hendrik J. Nel, Pascale Wehr, Nishta Ramnoruth, Swati Patel, Karin A. van Schie, Maxwell W. Bladen, Ahmed M. Mehdi, Joanne Tesiram, Meghna Talekar, Jamie Rossjohn, Hugh H. Reid, Frederik E. Stuurman, Helen Roberts, Phillip Vecchio, Ian Gourley, Mark Rigby, Stephane Becart, Rene E.M. Toes, Hans Ulrich Scherer, Kim-Anh Lê Cao, Kim Campbell, Ranjeny Thomas

Get full text

Incidence of febrile neutropenia during chemotherapy among patients with nonmyeloid cancer receiving filgrastim vs a filgrastim biosimilar by Schwartzberg LS, Lal LS, Balu S, Campbell K, Brekke L, Elliott C, Korrer S

“…Lee S Schwartzberg,1,2 Lincy S Lal,3 Sanjeev Balu,4 Kim Campbell,4 Lee Brekke,3 Caitlin Elliott,3 Stephanie Korrer3 1West Cancer Center, Memphis, TN, USA; 2Division of Hematology and Oncology, University of Tennessee, Memphis, TN, USA; 3Health Economics and Outcomes Research, Optum, Eden Prairie, MN, USA; 4US Clinical Development and Medical Affairs, Sandoz Inc., Princeton, NJ, USA Background: Filgrastim and other granulocyte colony-stimulating factors are recommended to decrease febrile neutropenia (FN) incidence among patients with nonmyeloid cancers undergoing chemotherapy. …”
Get full text